Biomm

Biomm FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biomm (BIOM3.SA) as of Nov 11, 2026 is 2,071.23 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 143.72 % — a change of 1,341.20% (higher).

FCF Conversion

2,071.23 %

YoY

1,341.20%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biomm is 2025 2,071.23 % . FCF Conversion Rate (FCF/EBITDA) of Biomm was 2024 143.72 % . It decreases by 1,341.20% higher compared to the previous year.

The Biomm FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
105.78 BRL
Jan 1, 2019
152.22 BRL
Jan 1, 2020
143.43 BRL
Jan 1, 2021
126.12 BRL
Jan 1, 2022
73.94 BRL
Jan 1, 2023
99.83 BRL
Jan 1, 2024
143.72 BRL
Jan 1, 2025
2,071.23 BRL
The Biomm FCF Conversion history
YEARFCF ConversionYoY
2,071.23 %+1,341.20%
143.72 %+43.95%
99.83 %+35.02%
73.94 %-41.37%
126.12 %-12.07%
143.43 %-5.77%
152.22 %+43.89%
105.78 %-33.01%
157.92 %-28.99%
222.40 %-138.20%
-582.14 %-270.82%
340.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

FCF Conversion Rate (FCF/EBITDA) of Biomm is 2,071.23 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Biomm changed from 143.72 % to 2,071.23 %, representing a 1,341.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biomm since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biomm

All Key Metrics — Biomm